Inclusion Criteria:

- Ability to understand and the willingness to sign a written informed consent
document.

- Patients must have histologically or cytologically confirmed breast carcinoma with
voluntarily elected breast conservation techniques (i.e., lumpectomy)

- Age >18 years. Breast cancer, while not restricted only to adult women, is rare in
the younger population.

- Radiation indicated as a post-surgical adjuvant treatment for breast conservation.

- Life expectancy of greater than 6 months.

- Karnofsky of greater or equal to 60

- The effects of radiation therapy on the developing human fetus at the recommended
therapeutic dose can be abortifacient. For this reason, and because radiation
therapy is known to be teratogenic, women of child-bearing potential and men must
agree to use adequate contraception (hormonal or barrier method of birth control;
abstinence) prior to study entry and for the duration of study participation. Should
a woman become pregnant or suspect she is pregnant while participating in this study,
she should inform her treating physician immediately.

Exclusion Criteria:

- Patients who have not recovered from adverse events due to agents administered more
than 4 weeks earlier.

- The inability to visualize or reliably contour the lumpectomy cavity from the
Radiation Oncology treatment planning CT scan.

- Patients with known brain metastases should be excluded from this clinical trial
because of their poor prognosis and because they often develop progressive neurologic
dysfunction that would confound the evaluation of neurologic and other adverse
events.

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements in the opinion of the principal investigator.

- Pregnant women are excluded from this study because radiation therapy has the
potential for teratogenic or abortifacient effects. Because there is an unknown but
potential risk for adverse events in nursing infants secondary to treatment of the
mother with standard chemotherapeutic regimens (if applicable), breastfeeding should
be discontinued if the mother is treated any adjuvant chemotherapy.